#China #Guangzhou #AMD #MingMed Biotechnology #QA102

MingMed Biotechnology Unveils Promising Results for QA102 in Treating Intermediate AMD

MingMed Biotechnology Co., Ltd has made waves in the medical community with the presentation of positive Phase II trial results for its innovative oral therapeutic, QA102, aimed at treating intermediate dry age-related macular degeneration (AMD). The trial results were unveiled at the prestigious Association for Research in Vision and Ophthalmology (ARVO) annual meeting held in Denver, Colorado, a significant gathering for researchers and clinicians in the ophthalmic field.

Understanding Intermediate AMD

Intermediate AMD is characterized by a gradual deterioration of the retina's cells, leading to a significant risk of progression to advanced stages of the disease, which can culminate in irreversible blindness. The condition is alarming, particularly among individuals aged 65 and older, representing a growing health concern as nearly 7% of this age group in the U.S. is affected. In this context, effective treatments are critically needed, making MingMed's development particularly noteworthy.

The Study: QA102-CS201

The clinical study, known as QA102-CS201, was meticulously designed as a Phase II, double-masked, randomized, placebo-controlled trial. It involved 150 participants who were diagnosed with intermediate atrophic AMD. These individuals were randomly assigned to receive either 200 mg or 400 mg doses of oral QA102, or a placebo, administered twice daily over a period of up to 15 months.

After 12 months of treatment, the results indicated a staggering 59.2% reduction in drusen volume for those receiving the 400 mg dose compared to the placebo group. While the primary endpoints did not highlight statistically significant differences between the groups, secondary measures provided promising indications of efficacy. Specifically, the rate of drusen growth showed a significant reduction of 118.2% (p=0.017) while the square-root transformed geographic atrophy (GA) area exhibited a 42.7% decrease in the treatment group compared to placebo (p=0.026). These findings suggest that QA102 has the potential to slow the progression of intermediate dry AMD while maintaining an acceptable safety profile.

Insights from Medical Experts

Dr. Scott Whitcup, an authority in ophthalmic drug development, emphasized the need for therapies for intermediate AMD, highlighting that the stage remains under-addressed despite its prevalence. He remarked, "The phase II data for QA102 are very encouraging for millions afflicted by intermediate or advanced forms of dry age-related macular degeneration." Similarly, Dr. Sunil Patel, the principal investigator of the study, echoed this sentiment, recognizing the potential impact of such advancements on public health.

Future Directions

Fred Ouyang, PhD, the Chief Technology Officer at MingMed Biotechnology, expressed excitement about presenting these compelling data to the global ophthalmology community. He noted that QA102 stands as a first-in-class oral therapy for atrophic AMD and is the first candidate to show efficacy signals in those patients suffering from intermediate dry AMD. The company is optimistic about moving QA102 into the next phase of clinical development to further substantiate its findings and explore its full therapeutic potential.

Conclusion

MingMed Biotechnology's innovative efforts are crucial in the fight against age-related ocular diseases, particularly in the intermediate phase of AMD, where options for patients have previously been quite limited. As they advance QA102 through further clinical development, the hope is that this groundbreaking therapy will lead to substantial improvements in patient outcomes and redefine standards of care for those suffering from this condition.